

MEDLINE database
Search: ACLF-Paper
Last Saved: 21.05.2023

("Liver Failure" [Mesh] OR "Failure, Acute on chronic Liver" OR "ACLF" OR "acute-on-chronic liver failure" OR "acute on chronic liver failure") AND
"Granulocyte Colony-Stimulating Factor" [Mesh] OR "G-CSF")

83 entries.

Cochrane DataBase
Search Name: ACLF-Paper
Last Saved: 21.05.2023
Comment:

ID	Search
#1	Title Abstract Keyword: Liver Failure
#2	Title Abstract Keyword: Failure, Acute on chronic liver
#3	Title Abstract Keyword: ACLF
#4	Title Abstract Keyword: acute on chronic liver failure
#5	Title Abstract Keyword: acute-on-chronic liver failure
#6	#1 OR #2 OR ## OR #4 OR #5
#7	Title Abstract Keyword: "granulocyte colony stimulating factor"
#8	Title Abstract Keyword: G-CSF
#9	#7 OR #8
#10	#6 AND #9


107 entries

SCOPUS Database
Search Name: ACLF paper
Last Saved: 21.05.2023

(TITLE-ABS-KEY("Liver Failure") OR TITLE-ABS-KEY("Failure, Acute on chronic Liver") OR TITLE-ABS-KEY("ACLF") OR TITLE-ABS-KEY("acute-on-chronic liver failure") OR TITLE-ABS-KEY("acute on chronic liver failure")) AND (TITLE-ABS-KEY("Granulocyte Colony-Stimulating Factor") OR TITLE-ABS-KEY("G-CSF"))


533 entries

Suppl. Figure 1. Overall survival, sensitivity analysis Risk of bias



Duan XZ [29], Engelmann C [19], Garg V [30], Saha BK [31], Tong J [32]


Suppl. Figure 2. Overall survival, sensitivity analysis ACLF criteria



Duan XZ [29], Garg V [30], Saha BK [31], Tong J [32]


Suppl. Figure 3.

a) Overall survival, sensitivity analysis follow-up 30 days




Engelmann C [19], Garg V [30], Saha BK [31], Tong J [32]

b) Overall survival, sensitivity analysis follow-up 60 days




Duan XZ [29], Engelmann C [19], Garg V [30], Saha BK [31], Tong J [32]

c) Overall survival, sensitivity analysis follow-up 90 days




Duan XZ [29], Engelmann C [19], Garg V [30], Saha BK [31], Tong J [32]

Suppl.Figure 4. Overall survival, sensitivity analysis with competing risk analysis data




Duan XZ [29], Engelmann C [19], Garg V [30], Saha BK [31], Tong J [32]


Suppl.Figure 5. MELD score, sensitivity analysis follow-up 30 days




Suppl.Figure 6. MELD score, sensitivity analysis risk of bias



Suppl.Figure 7. MELD score, sensitivity analysis ACLF criteria




Suppl.Figure 8. MELD score, post-hoc analysis available case




Duan XZ [29], Engelmann C [19], Garg V [30], Saha BK [31]

Suppl.Figure 9. Child-Pugh score, sensitivity analysis statistical values



Duan XZ [29], Garg V [30], Saha BK [31]


Suppl.Figure 10. Child-Pugh score, sensitivity analysis 30 days follow-up



Random-effects REML model

Duan XZ [29], Garg V [30], Saha BK [31]


Suppl.Figure 11. Child-Pugh score, post-hoc analysis available case




Random-effects REML model

Duan XZ [29], Garg V [30], Saha BK [31]

Suppl.Figure 12. Mortality, sensitivity analysis EASL criteria




Suppl.Figure 13. Mortality, sensitivity analysis risk of bias




Duan XZ [29], Engelmann C [19], Garg V [30], Saha BK [31], Tong J [32]

Suppl.Figure 14. Cirrhotic complications, sensitivity analysis risk of bias



Duan XZ [29], Engelmann C [19], Tong J [32]

Suppl.Figure 15. Cirrhotic complications, sensitivity analysis EASL criteria



Supplementary Table 1: Risk of bias assessment for primary outcome overall survival with Cochrane RoB tool 2.0

First Author, Year, Country	Randomization process	Deviations from intended interventions	Missing outcome data	Measurement of the outcome	Selection of the reported result	Overall Bias
Saha BK, 2017, India	Some concerns	Low	Low	Low	Low	Some concerns
Engelmann C, 2021, Germany	Low	Low	Low	Low	Low	Low
Duan XZ, 2013, China	Low	Low	Low	Low	Low	Low
Garg V, 2021, India	Some concerns	Low	Low	Low	Low	Some concerns
Tong J, 2022, China	Low	Low	Low	Low	Low	Low

Duan XZ [29], Engelmann C [19], Garg V [30], Saha BK [31], Tong J [32]

Saha BK [31], 2017, India :

Randomization: The grouping was done as per the visit of the patients to the hospital

Deviations from intended interventions: Low

Missing outcome data: sufficient information has been provided

Measurement of the outcome: Low risk

Selection of the reported result: Low risk

Engelmann C [19], 2021, Germany

Randomization: Web-based allocation sequence generation

Deviations from intended interventions: Low

Missing outcome data: sufficient information has been provided

Measurement of the outcome: Low risk
 Selection of the reported result: Low risk
 Duan XZ[29], 2013, India
 Randomization: double blind, placebo-controlled
 Deviations from intended interventions: Low risk
 Missing outcome data: ITT analysis
 Measurement of the outcome: Low risk
 Selection of the reported result: Low risk
 Garg V[30], 2021, India
 Randomization: Some concerns
 Deviations from intended interventions: Low risk
 Missing outcome data: Reasons for missing outcome data unlikely to be related to true outcome
 Measurement of the outcome: Low risk
 Selection of the reported result: Low risk
 Tong JJ[32], 2022, China
 Randomization: randomized allocation sequence generation
 Deviations from intended interventions: Low
 Missing outcome data: sufficient information has been provided
 Measurement of the outcome: Low risk
 Selection of the reported result: Low risk

Suppl.Table 2, Main differences between APASL and EASL criteria

Parameters	APASL definition	AASLD/EASL working party definition
Duration between acute insult and ACLF	Four weeks	Not defined
Underlying chronic liver disease	Non-cirrhotic chronic liver disease and only compensated cirrhosis	Only cirrhosis, non-cirrhotic chronic liver disease excluded
Acute precipitating event	Alcohol, drugs, hepatotropic viruses, surgery, trauma	Alcohol, drugs, hepatotropic viruses, surgery, trauma, infection/sepsis, variceal bleed
Organ Failure	Hepatic failure	Extra-hepatic organ failure